Status:
COMPLETED
Effects of Pennsaid on Clinical Neuropathic Pain
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Neuralgia
Postherpetic Neuralgia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain felt by people with chronic nerve pain. The drug will be used 2-4 times each day for 2 weeks. The U.S. Food ...
Detailed Description
The research study will compare Pennsaid to placebo. The placebo looks like Pennsaid, but it doesn't contain any Pennsaid. The investigators use placebos in research to see if the results are due to t...
Eligibility Criteria
Inclusion
- Subject will be between 18 and 80 years of age.
- Subject has not been on Pennsaid or other topical non-steroid anti-inflammatory drugs for at least one month.
- Subject agrees to make no change in his/her current pain medications during the entire study period. This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study.
- Subject has a VAS pain score of 4 or above at the beginning of the study.
- Subject has had a neuropathic pain condition such as those listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.
- Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.
Exclusion
- Subject has documented severe liver or renal disease that will affect the elimination of Pennsaid or is subject to the adverse effect of Pennsaid on these organs. (Renal dysfunction is defined as eGFR \< 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)
- Subject has pending litigation related to the neuropathic pain condition.
- Subject has active skin lesion or open wound at the site of Pennsaid application (e.g., active shingles with skin lesions).
- Subject is pregnant or lactating.
- Subject has scar tissue or sensory deficit at the site of QST.
- Subject is allergic to diclofenac or has cross-sensitivity to other non-steroid anti-inflammatory drugs.
- Subject has a positive urine (illicit) drug test.
- Subjects who experience asthma, urticaria or an allergic type reaction when taking aspirin or NSAIDs.
- Subjects undergoing coronary artery bypass surgery.
- Subject with a known history of cardiovascular disease, ulcer, gastrointestinal bleed or impaired renal function.
- Subjects currently using NSAIDS.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01508676
Start Date
November 1 2011
End Date
January 1 2016
Last Update
February 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MGH Center for Translational Pain Research
Boston, Massachusetts, United States, 02114